[Oxidative stress and endothelial dysfunction].
Growing numbers of morbidity and mortality due to the Coronary Heart Disease (CHD) is recognized as the more increasing challenge in the world. The initial stage of atherosclerosis, early diagnosis and treatment of CHD are the main objectives of current research. Endothelium dysfunction, the earliest expression of the atherosclerotic process is associated with subtle biochemical changes that gradually are transformed into the structural changes of the arterial wall. The theory of free radicals is the most common among the atherosclerosis explanations. Overproduction or impaired neutralization of the free radicals accounts for oxidative stress that is causing substantial damage to the low density lipoproteins, nitric oxyde (NO), endothelium cells, tissue cells and finally leads to the endothelium dysfuction. Pathophysiology of oxidative stress and its role in the endothelium dysfunction are discussed in this paper. Positive role of various medications (statins, angiotensin converting enzym inhibitors, aldosteron antagonists, estrogens, antioxidants, b-blockers with vasodilatative properties) to the oxidative stress and consequently to the endothelium dysfuction are discussed as well.
Jarasūniene
Dalia
D
Klaipeda Seamen's Hospital, Liepojos 45, 5809 Klaipeda, Lithuania. dalijara@delfi.lt
Simaitis
Audrius
A
D000367:Age Factors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D018849:Controlled Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D048909:Diabetes Complications; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000503:physiopathology*; D004967:Estrogens / Q000627:therapeutic use; D005609:Free Radicals; D000882:Haplorhini; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D018384:Oxidative Stress; D010919:Placebos; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000975:Antioxidants; D004967:Estrogens; D005609:Free Radicals; D000960:Hypolipidemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos